$GTHP
GUIDED THERAPEUTICS INC Stock $gthp

$gthp Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000147793224007162 Filed on November 14, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$0.00
YoY Change
Cost Of Revenue		$0.00
YoY Change		-100.0%
Gross Profit		$0.00
YoY Change		-100.0%
Gross Profit Margin
Selling, General & Admin		$450.0K
YoY Change		-18.18%
% of Gross Profit
Research & Development		$111.0K
YoY Change		60.87%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses		$561.0K
YoY Change		-9.37%
Operating Profit		-$561.0K
YoY Change		-9.95%
Interest Expense		$108.0K
YoY Change		52.11%
% of Operating Profit
Other Income/Expense, Net		-$93.00K
YoY Change		72.22%
Pretax Income		-$654.0K
YoY Change		-3.4%
Income Tax		$0.00
% Of Pretax Income
Net Earnings		-$654.0K
YoY Change		-3.4%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.01
Diluted Earnings Per Share		-$0.01
COMMON SHARES
Basic Shares Outstanding	61.02M shares	56.55M shares
Diluted Shares Outstanding		57.04M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents		$194.0K
Short-Term Investments
Other Short-Term Assets		$211.0K
YoY Change		9.9%
Inventory		$636.0K
Prepaid Expenses
Receivables		$2.000K
Other Receivables
Total Short-Term Assets		$1.043M
YoY Change		-33.9%
LONG-TERM ASSETS
Property, Plant & Equipment		$25.00K
YoY Change		-28.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$17.00K
YoY Change		0.0%
Total Long-Term Assets		$206.0K
YoY Change		-31.1%
TOTAL ASSETS
Total Short-Term Assets		$1.043M
Total Long-Term Assets		$206.0K
Total Assets		$1.249M
YoY Change		-33.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$2.100M
YoY Change		-2.46%
Accrued Expenses		$923.0K
YoY Change		14.37%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$6.025M
YoY Change		24.64%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$142.0K
YoY Change		-79.51%
TOTAL LIABILITIES
Total Short-Term Liabilities		$6.025M
Total Long-Term Liabilities		$142.0K
Total Liabilities		$6.167M
YoY Change		11.58%
SHAREHOLDERS EQUITY
Retained Earnings		-$153.0M
YoY Change		1.57%
Common Stock		$3.446M
YoY Change		0.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$132.0K
YoY Change		0.0%
Treasury Stock Shares
Shareholders Equity		-$4.918M
YoY Change
Total Liabilities & Shareholders Equity		$1.249M
YoY Change		-33.46%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$654.0K
YoY Change		-3.4%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	216000	usd
CY2024Q3	us-gaap	Interest Payable Current InterestPayableCurrent	188000	usd
CY2024Q3	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	31000	usd
CY2024Q3	us-gaap	Dividends Payable Current DividendsPayableCurrent	188000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	8000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1068000	usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue	424225	usd
CY2023Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	7442	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1500	usd
	us-gaap	Premiums Percentage Assumed To Net PremiumsPercentageAssumedToNet	0.500	pure
CY2024Q3	gthp	Working Capital WorkingCapital	-5000000	usd
CY2024Q3	gthp	Retained Earning Accumulated Deficit RetainedEarningAccumulatedDeficit	-153000000	usd
	gthp	Net Loss Preferred Dividend NetLossPreferredDividend	-1900000	usd
CY2024Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	1364000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1360000	usd
CY2024Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	46000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	46000	usd
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	44000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	44000	usd
CY2024Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	818000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	818000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	636000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	632000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1614000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1614000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1589000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1582000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	32000	usd
CY2024Q3	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	383000	usd
CY2023Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	401000	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	126000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	188000	usd
CY2023Q4	us-gaap	Accrued Vacation Current And Noncurrent AccruedVacationCurrentAndNoncurrent	27000	usd
CY2023Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	228000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	7000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	923000	usd
CY2024Q3	us-gaap	Deferred Revenue DeferredRevenue	747780	usd
CY2024Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	2047	usd
CY2024Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	450	usd
CY2024Q3	gthp	Remaining Net Operating Losses RemainingNetOperatingLosses	3800000	usd
CY2024Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2500000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2338636	shares
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	0.41
	gthp	Weighted Average Remaining Contractual Life Beginning WeightedAverageRemainingContractualLifeBeginning	P6Y6M
CY2023Q4	gthp	Agrregate Intrensic Value AgrregateIntrensicValue	0	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2883636	shares
CY2024Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	0.35
	gthp	Weighted Average Remaining Contractual Life Ending WeightedAverageRemainingContractualLifeEnding	P6Y7M6D
CY2024Q3	gthp	Agrregate Intrensic Value AgrregateIntrensicValue	29975	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2172614	shares
	gthp	Weighted Average Exercise Price Per Share Exercisable WeightedAverageExercisePricePerShareExercisable	0.41
	gthp	Weighted Average Remaining Contractual Life Exercisable WeightedAverageRemainingContractualLifeExercisable	P5Y8M12D
	gthp	Agrregate Intrensic Value Exercisable AgrregateIntrensicValueExercisable	7494	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1500000	shares
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	0.49
	gthp	Weighted Average Remaining Contractual Life Beginning WeightedAverageRemainingContractualLifeBeginning	P7Y6M
CY2022Q4	gthp	Agrregate Intrensic Value AgrregateIntrensicValue	0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1025000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.26
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	186364	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.31
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2338636	shares
CY2023Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	0.41
	gthp	Weighted Average Remaining Contractual Life Ending WeightedAverageRemainingContractualLifeEnding	P6Y9M18D
CY2023Q3	gthp	Agrregate Intrensic Value AgrregateIntrensicValue	0	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1811364	shares
	gthp	Weighted Average Exercise Price Per Share Exercisable WeightedAverageExercisePricePerShareExercisable	0.45
	gthp	Weighted Average Remaining Contractual Life Exercisable WeightedAverageRemainingContractualLifeExercisable	P6Y
	gthp	Agrregate Intrensic Value Exercisable AgrregateIntrensicValueExercisable	0	usd
	gthp	Unrecognized Stock Based Compensation Expense UnrecognizedStockBasedCompensationExpense	128792	usd
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.12
CY2023Q1	gthp	Vesting Period Description VestingPeriodDescription	One fourth of the stock options vested immediately, while the remaining options will vest over a period of 33 months, beginning on June 7, 2023
	us-gaap	Operating Lease Expense OperatingLeaseExpense	27351	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	164000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	227000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	178000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	246000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	29000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	118000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	50000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	197000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	19000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	178000	usd
	us-gaap	Finite Lived Intangible Asset Weighted Average Period Before Next Renewal Or Extension FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension	P1Y8M12D
CY2023	us-gaap	Finite Lived Intangible Asset Weighted Average Period Before Next Renewal Or Extension FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension	P2Y4M24D
	gthp	Weighted Average Discount Rate Operating Lease WeightedAverageDiscountRateOperatingLease	0.114	pure
CY2023	gthp	Weighted Average Discount Rate Operating Lease WeightedAverageDiscountRateOperatingLease	0.114	pure
CY2016Q2	gthp	Royalty Percent RoyaltyPercent	0.20	pure
CY2020Q1	gthp	Warrants Broken Into Four Tranches WarrantsBrokenIntoFourTranches	1250000	shares
CY2020Q1	us-gaap	Share Price SharePrice	0.25
CY2019Q4	us-gaap	Convertible Debt ConvertibleDebt	2400000	usd
CY2024Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.24	pure
	gthp	Convertible Debt Conversion Price Description ConvertibleDebtConversionPriceDescription	The variable conversion price was 95% multiplied by the market price (the market price means the average of the five lowest trading prices during the period beginning on the issue date and ending on the maturity date)
CY2019Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.04
CY2019Q4	gthp	Variable Conversion Price VariableConversionPrice	0.15
CY2022Q3	gthp	Default Premiums DefaultPremiums	281256	usd
CY2022Q3	gthp	Interest Payable InterestPayable	91555	usd
CY2022Q3	gthp	Amount Reduce After Exchange AmountReduceAfterExchange	710911	usd
CY2022Q3	gthp	Warrant Exchange WarrantExchange	8775000	shares
CY2022Q3	gthp	Early Repayment Of Senior Debt Penalty EarlyRepaymentOfSeniorDebtPenalty	350000	usd
CY2022Q3	gthp	Debt Instrument Default Penalty Forgiven DebtInstrumentDefaultPenaltyForgiven	225444	usd
CY2024Q3	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	57954585	shares
CY2023Q3	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	54457934	shares
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1891000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3290000	usd
	us-gaap	Weighted Average Number Basic Shares Outstanding Adjustment Pro Forma WeightedAverageNumberBasicSharesOutstandingAdjustmentProForma	55929000	shares
	us-gaap	Weighted Average Number Basic Shares Outstanding Adjustment Pro Forma WeightedAverageNumberBasicSharesOutstandingAdjustmentProForma	50588000	shares
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.03
	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.07
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	55929000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	50588000	shares
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.03
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.07
CY2024Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	66400000	usd
CY2024Q2	us-gaap	Notes Payable NotesPayable	100000	usd
CY2024Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.25
CY2024Q2	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	81768	usd
CY2024Q2	us-gaap	Notes Payable NotesPayable	87162	usd
CY2024Q2	us-gaap	Repayments Of Debt RepaymentsOfDebt	2000	usd
CY2024Q2	gthp	Accrued Interest Rate AccruedInterestRate	0.060	pure
CY2024Q2	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2028-05-05
CY2023Q3	us-gaap	Line Of Credit Facility Average Outstanding Amount LineOfCreditFacilityAverageOutstandingAmount	129073	usd
CY2023Q3	us-gaap	Repayments Of Debt RepaymentsOfDebt	12041	usd
CY2023Q3	gthp	Accrued Interest Rate AccruedInterestRate	0.079	pure
CY2023Q3	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2024-05-04
CY2024Q3	us-gaap	Shortterm Debt Fair Value ShorttermDebtFairValue	20000	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0000924515
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q3	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	0	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	818000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54105000	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	60457000	shares
CY2023Q4	gthp	Excessed Amount Of Insured Limitations ExcessedAmountOfInsuredLimitations	156112	usd
CY2023Q4	gthp	Outstanding Principal Balance Note Payable OutstandingPrincipalBalanceNotePayable	59422	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Entity File Number EntityFileNumber	000-22179
	dei	Entity Registrant Name EntityRegistrantName	GUIDED THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	58-2029543
	dei	Entity Address Address Line1 EntityAddressAddressLine1	5835 Peachtree Corners East
	dei	Entity Address City Or Town EntityAddressCityOrTown	Peachtree Corners
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite B
	dei	Entity Address City Or Town EntityAddressCityOrTown	Peachtree Corners
	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	30092
	dei	City Area Code CityAreaCode	770
	dei	Local Phone Number LocalPhoneNumber	242-8723
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	61015237	shares
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	194000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	591000	usd
CY2023Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	2000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7000	usd
CY2024Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	818000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	636000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	632000	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	211000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	163000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	1043000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1393000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	32000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	164000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	227000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	17000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	17000	usd
CY2024Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	206000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	276000	usd
CY2024Q3	us-gaap	Assets Assets	1249000	usd
CY2023Q4	us-gaap	Assets Assets	1669000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2100000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1991000	usd
CY2024Q3	gthp	Account Payable Related Parties Current AccountPayableRelatedPartiesCurrent	32000	usd
CY2023Q4	gthp	Account Payable Related Parties Current AccountPayableRelatedPartiesCurrent	32000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	923000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1068000	usd
CY2024Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	748000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	424000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	102000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	91000	usd
CY2024Q3	gthp	Short Term Notes Payable Due To Related Parties ShortTermNotesPayableDueToRelatedParties	68000	usd
CY2023Q4	gthp	Short Term Notes Payable Due To Related Parties ShortTermNotesPayableDueToRelatedParties	0	usd
CY2024Q3	gthp	Current Portion Of Long Term Debt Related Parties CurrentPortionOfLongTermDebtRelatedParties	525000	usd
CY2023Q4	gthp	Current Portion Of Long Term Debt Related Parties CurrentPortionOfLongTermDebtRelatedParties	39000	usd
CY2024Q3	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	228000	usd
CY2023Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	59000	usd
CY2024Q3	gthp	Short Term Convertible Notes Payable Including Nonconvertible Penalty ShortTermConvertibleNotesPayableIncludingNonconvertiblePenalty	149000	usd
CY2023Q4	gthp	Short Term Convertible Notes Payable Including Nonconvertible Penalty ShortTermConvertibleNotesPayableIncludingNonconvertiblePenalty	1105000	usd
CY2024Q3	us-gaap	Debt Default Shortterm Debt Amount DebtDefaultShorttermDebtAmount	1130000	usd
CY2023Q4	us-gaap	Debt Default Shortterm Debt Amount DebtDefaultShorttermDebtAmount	0	usd
CY2024Q3	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	20000	usd
CY2023Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	0	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6025000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4809000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	76000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	155000	usd
CY2024Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	53000	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	usd
CY2024Q3	gthp	Current Portion Of Long Term Debt Related Parties Non Current CurrentPortionOfLongTermDebtRelatedPartiesNonCurrent	13000	usd
CY2023Q4	gthp	Current Portion Of Long Term Debt Related Parties Non Current CurrentPortionOfLongTermDebtRelatedPartiesNonCurrent	511000	usd
CY2024Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	142000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	666000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	6167000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	5475000	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	60457000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54105000	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	3446000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3441000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	141757000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	140983000	usd
CY2024Q3	us-gaap	Treasury Stock Value TreasuryStockValue	132000	usd
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	132000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-153009000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-151118000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-4918000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-3806000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1249000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1669000	usd
CY2024Q3	us-gaap	Revenues Revenues	0	usd
CY2023Q3	us-gaap	Revenues Revenues	0	usd
	us-gaap	Revenues Revenues	6000	usd
	us-gaap	Revenues Revenues	66000	usd
CY2024Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	46000	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	0	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	-4000	usd
	us-gaap	Gross Profit GrossProfit	4000	usd
	us-gaap	Gross Profit GrossProfit	20000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	111000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	69000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	386000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	142000	usd
CY2024Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	76000	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	69000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	218000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	203000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	374000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	481000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	974000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2647000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	561000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	619000	usd
	us-gaap	Operating Expenses OperatingExpenses	1578000	usd
	us-gaap	Operating Expenses OperatingExpenses	2992000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-561000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-623000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1574000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2972000	usd
CY2024Q3	us-gaap	Interest Expense InterestExpense	108000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	71000	usd
	us-gaap	Interest Expense InterestExpense	247000	usd
	us-gaap	Interest Expense InterestExpense	206000	usd
CY2024Q3	us-gaap	Interest Income Operating InterestIncomeOperating	0	usd
CY2023Q3	us-gaap	Interest Income Operating InterestIncomeOperating	0	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	3000	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	0	usd
CY2024Q3	gthp	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	-1000	usd
CY2023Q3	gthp	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	0	usd
	gthp	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	-8000	usd
	gthp	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	5000	usd
CY2024Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	16000	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	17000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	49000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	69000	usd
CY2024Q3	us-gaap	Other Income OtherIncome	0	usd
CY2023Q3	us-gaap	Other Income OtherIncome	0	usd
	us-gaap	Other Income OtherIncome	12000	usd
	us-gaap	Other Income OtherIncome	1000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-93000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-54000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-191000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-131000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-654000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-677000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1765000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3103000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-654000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-677000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1765000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3103000	usd
CY2024Q3	gthp	Deemed Dividend For Warrant Exchanges DeemedDividendForWarrantExchanges	0	usd
CY2023Q3	gthp	Deemed Dividend For Warrant Exchanges DeemedDividendForWarrantExchanges	0	usd
	gthp	Deemed Dividend For Warrant Exchanges DeemedDividendForWarrantExchanges	0	usd
	gthp	Deemed Dividend For Warrant Exchanges DeemedDividendForWarrantExchanges	-65000	usd
CY2024Q3	us-gaap	Dividends Preferred Stock DividendsPreferredStock	38000	usd
CY2023Q3	us-gaap	Dividends Preferred Stock DividendsPreferredStock	40000	usd
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	126000	usd
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	122000	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-692000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-717000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1891000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3290000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57039000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	51473000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55929000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	50588000	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	57039000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	51473000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55929000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	50588000	shares
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-4667000	usd
CY2024Q3	gthp	Issuance Of Common Stock And Warrants In Private Placement Offering Net Of Expenses Amount IssuanceOfCommonStockAndWarrantsInPrivatePlacementOfferingNetOfExpensesAmount	300000	usd
CY2024Q3	gthp	Issuance Of Common Stock For Payment Of Series D Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesDPreferredDividendsAmount	9000	usd
CY2024Q3	gthp	Issuance Of Common Stock For Payment Of Series E Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesEPreferredDividendsAmount	55000	usd
CY2024Q3	gthp	Issuance Of Common Stock For Payment Of Interest Amount IssuanceOfCommonStockForPaymentOfInterestAmount	21000	usd
CY2024Q3	gthp	Issuance Of Warrants With Debt IssuanceOfWarrantsWithDebt	15000	usd
CY2024Q3	gthp	Stock Based Compensation StockBasedCompensation	41000	usd
CY2024Q3	gthp	Accrued Preferred Dividends AccruedPreferredDividends	-38000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-654000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-4918000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-3806000	usd
	gthp	Issuance Of Common Stock And Warrants In Private Placement Offering Net Of Expenses Amount IssuanceOfCommonStockAndWarrantsInPrivatePlacementOfferingNetOfExpensesAmount	300000	usd
	gthp	Issuance Of Common Stock For Payment Of Series D Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesDPreferredDividendsAmount	24000	usd
	gthp	Issuance Of Common Stock For Payment Of Series E Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesEPreferredDividendsAmount	63000	usd
	gthp	Issuance Of Common Stock For Payment Of Series F Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesFPreferredDividendsAmount	54000	usd
	gthp	Issuance Of Common Stock For Payment Of Series F2 Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesF2PreferredDividendsAmount	27000	usd
	gthp	Issuance Of Common Stock For Payment Of Interest Amount IssuanceOfCommonStockForPaymentOfInterestAmount	126000	usd
	gthp	Settlement Of Previously Accrued Professional Fees Through Common Stock Issuance Amount SettlementOfPreviouslyAccruedProfessionalFeesThroughCommonStockIssuanceAmount	57000	usd
	gthp	Issuance Of Warrants With Debt IssuanceOfWarrantsWithDebt	27000	usd
	gthp	Stock Based Compensation StockBasedCompensation	101000	usd
	gthp	Accrued Preferred Dividends AccruedPreferredDividends	-126000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1765000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-4918000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-3315000	usd
CY2023Q3	gthp	Issuance Of Common Stock For Payment Of Series D Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesDPreferredDividendsAmount	8000	usd
CY2023Q3	gthp	Issuance Of Common Stock For Payment Of Series E Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesEPreferredDividendsAmount	53000	usd
CY2023Q3	gthp	Issuance Of Common Stock For Payment Of Interest Amount IssuanceOfCommonStockForPaymentOfInterestAmount	60000	usd
CY2023Q3	gthp	Settlement Of Previously Accrued Professional Fees Through Common Stock Issuance Amount SettlementOfPreviouslyAccruedProfessionalFeesThroughCommonStockIssuanceAmount	51000	usd
CY2023Q3	gthp	Stock Based Compensation StockBasedCompensation	210000	usd
CY2023Q3	gthp	Accrued Preferred Dividends AccruedPreferredDividends	-40000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-677000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-3650000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2883000	usd
	gthp	Common Stock Warrants Exercised Amount CommonStockWarrantsExercisedAmount	231000	usd
	gthp	Issuance Of Common Stock For Payment Of Series D Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesDPreferredDividendsAmount	22000	usd
	gthp	Issuance Of Common Stock For Payment Of Series E Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesEPreferredDividendsAmount	61000	usd
	gthp	Issuance Of Common Stock For Payment Of Series F Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesFPreferredDividendsAmount	53000	usd
	gthp	Issuance Of Common Stock For Payment Of Series F2 Preferred Dividends Amount IssuanceOfCommonStockForPaymentOfSeriesF2PreferredDividendsAmount	29000	usd
	gthp	Conversion Of Series E Preferred Stock To Common Stock Amount ConversionOfSeriesEPreferredStockToCommonStockAmount	0	usd
	gthp	Conversion Of Series F Preferred Stock To Common Stock Amount ConversionOfSeriesFPreferredStockToCommonStockAmount	0	usd
	gthp	Conversion Of Series F2 Preferred Stock To Common Stock Amount ConversionOfSeriesF2PreferredStockToCommonStockAmount	0	usd
	gthp	Issuance Of Common Stock For Payment Of Interest Amount IssuanceOfCommonStockForPaymentOfInterestAmount	119000	usd
	gthp	Settlement Of Previously Accrued Professional Fees Through Common Stock Issuance Amount SettlementOfPreviouslyAccruedProfessionalFeesThroughCommonStockIssuanceAmount	168000	usd
	gthp	Stock Based Compensation StockBasedCompensation	1776000	usd
	gthp	Impact Of Warrant Exchanges ImpactOfWarrantExchanges	0	usd
	gthp	Accrued Preferred Dividends AccruedPreferredDividends	-123000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3103000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-3650000	usd
	us-gaap	Profit Loss ProfitLoss	1765000	usd
	us-gaap	Profit Loss ProfitLoss	3103000	usd
	gthp	Bad Debt Expense BadDebtExpense	1000	usd
	gthp	Bad Debt Expense BadDebtExpense	2000	usd
	us-gaap	Depreciation Depreciation	7000	usd
	us-gaap	Depreciation Depreciation	7000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	72000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	97000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	133000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1860000	usd
	us-gaap	Servicing Liability At Fair Value Other Changes In Fair Value ServicingLiabilityAtFairValueOtherChangesInFairValue	-8000	usd
	us-gaap	Servicing Liability At Fair Value Other Changes In Fair Value ServicingLiabilityAtFairValueOtherChangesInFairValue	5000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	64000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	56000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	49000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	69000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-14000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-20000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	99000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-82000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-74000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	389000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-130000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-67000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-58000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	324000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-59000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-787000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1410000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	312000	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
	gthp	Proceeds From The Issuance Of Notes Payable Issued To Related Parties ProceedsFromTheIssuanceOfNotesPayableIssuedToRelatedParties	75000	usd
	gthp	Proceeds From The Issuance Of Notes Payable Issued To Related Parties ProceedsFromTheIssuanceOfNotesPayableIssuedToRelatedParties	0	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	239000	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	367000	usd
	gthp	Repayments Of Notes Payable Issued To Related Parties RepaymentsOfNotesPayableIssuedToRelatedParties	29000	usd
	gthp	Repayments Of Notes Payable Issued To Related Parties RepaymentsOfNotesPayableIssuedToRelatedParties	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	29000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	300000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	195000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	390000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-172000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-397000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1582000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	591000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2313000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	194000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	731000	usd
	us-gaap	Interest Paid Net InterestPaidNet	25000	usd
	us-gaap	Interest Paid Net InterestPaidNet	97000	usd
	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	126000	usd
	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	122000	usd
	gthp	Deemed Dividends For Warrant Exchanges DeemedDividendsForWarrantExchanges	0	usd
	gthp	Deemed Dividends For Warrant Exchanges DeemedDividendsForWarrantExchanges	65000	usd
	gthp	Warrants Issued With Debt WarrantsIssuedWithDebt	27000	usd
	gthp	Warrants Issued With Debt WarrantsIssuedWithDebt	0	usd
	gthp	Fair Value Of Beneficial Conversion Features FairValueOfBeneficialConversionFeatures	12000	usd
	gthp	Fair Value Of Beneficial Conversion Features FairValueOfBeneficialConversionFeatures	0	usd
	gthp	Settlement Of Interest Through Common Stock Issuance SettlementOfInterestThroughCommonStockIssuance	126000	usd
	gthp	Settlement Of Interest Through Common Stock Issuance SettlementOfInterestThroughCommonStockIssuance	119000	usd
	gthp	Settlement Of Dividends Through Common Stock Issuance SettlementOfDividendsThroughCommonStockIssuance	168000	usd
	gthp	Settlement Of Dividends Through Common Stock Issuance SettlementOfDividendsThroughCommonStockIssuance	166000	usd
	gthp	Settlement Of Previously Accrued Professional Fees Through Common Stock Issuance SettlementOfPreviouslyAccruedProfessionalFeesThroughCommonStockIssuance	57000	usd
	gthp	Settlement Of Previously Accrued Professional Fees Through Common Stock Issuance SettlementOfPreviouslyAccruedProfessionalFeesThroughCommonStockIssuance	167000	usd
	gthp	Accrued Payroll Liability Exchanged For Promissory Note AccruedPayrollLiabilityExchangedForPromissoryNote	87000	usd
	gthp	Accrued Payroll Liability Exchanged For Promissory Note AccruedPayrollLiabilityExchangedForPromissoryNote	0	usd
	gthp	Directors And Officers Insurance Obtained With Financing DirectorsAndOfficersInsuranceObtainedWithFinancing	130000	usd
	gthp	Directors And Officers Insurance Obtained With Financing DirectorsAndOfficersInsuranceObtainedWithFinancing	119000	usd
	gthp	Conversion Of Series E Preferred Shares Into Common Stock ConversionOfSeriesEPreferredSharesIntoCommonStock	0	usd
	gthp	Conversion Of Series E Preferred Shares Into Common Stock ConversionOfSeriesEPreferredSharesIntoCommonStock	5000	usd
	gthp	Conversion Of Series F Preferred Shares Into Common Stock ConversionOfSeriesFPreferredSharesIntoCommonStock	0	usd
	gthp	Conversion Of Series F Preferred Shares Into Common Stock ConversionOfSeriesFPreferredSharesIntoCommonStock	42000	usd
	gthp	Conversion Of Series F2 Preferred Shares Into Common Stock ConversionOfSeriesF2PreferredSharesIntoCommonStock	0	usd
	gthp	Conversion Of Series F2 Preferred Shares Into Common Stock ConversionOfSeriesF2PreferredSharesIntoCommonStock	14000	usd
CY2024Q3	gthp	Stockholders Deficits StockholdersDeficits	-4900000	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	400000	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	400000	usd
	gthp	Proceeds From Sale Of Common Stock ProceedsFromSaleOfCommonStock	300000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the inventory valuation, valuation of share-based compensation and the valuation of the convertible note payable derivative liability. Management bases its estimates on historical experience and on various other assumptions believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates, and such differences could be material to the Company’s financial statements.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company maintains a cash balance in a financial institution that is insured by the Federal Deposit Insurance Corporation up to certain federal limitations. At times, the Company’s cash balance exceeds these federal limitations. The amount in excess of insured limitations was nil and $156,112 as of September 30, 2024 and December 31, 2023, respectively.</p>
CY2024Q3	gthp	Excessed Amount Of Insured Limitations ExcessedAmountOfInsuredLimitations	156112	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	509101	usd
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6351783	shares
	gthp	Common Shares Issued CommonSharesIssued	6351783	shares
CY2023Q4	us-gaap	Shares Outstanding SharesOutstanding	54105101	shares
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6351783	shares
CY2024Q3	us-gaap	Shares Outstanding SharesOutstanding	60456884	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	28584580	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.50
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	5368335	shares
	gthp	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Warrant Issued ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceWarrantIssued	0.19
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	1561500	shares
	gthp	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceExpired	0.44
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	32391415	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.46
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	35586980	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.46
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	6773750	shares
	gthp	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Warrant Issued ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePriceWarrantIssued	0.26
	gthp	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exchanged ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExchanged	-1025000	usd
	gthp	Share Based Compensation Arrangement By Share Based Payment Award Options For Exchange In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForExchangeInPeriodWeightedAverageExercisePrice	0.25
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	9545200	shares
	gthp	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceExpired	0.30
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	973750	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.20
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	30816780	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.49
	gthp	Schedule Of Fair Value Warrants Issued Under Black Scholes Option Pricing Model Table Textblock ScheduleOfFairValueWarrantsIssuedUnderBlackScholesOptionPricingModelTableTextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected term (years)</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.0</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">397.3</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Risk-free interest rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.5</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Dividend yield</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="width:16%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expected term (years)</p></td><td style="width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">3.8</p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="width:15%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Volatility</p></td><td style="width:1%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">266.4%</p></td></tr><tr style="height:15px;background-color:#cceeff"><td colspan="2" style="width:16%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Risk-free interest rate</p></td><td style="width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">3.8%</p></td></tr><tr style="height:15px;background-color:#ffffff"><td colspan="2" style="width:16%;vertical-align:bottom;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Dividend yield</p></td><td style="width:8%;vertical-align:bottom;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">0.0%</p></td></tr></tbody></table>
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	3.973	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.035	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y9M18D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	2.664	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.038	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	545000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.12
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.26
	gthp	Expiration Date ExpirationDate	2034-07-08
	gthp	Vesting Period Description VestingPeriodDescription	while the remaining options will vest over a period of 33 months, beginning on October 9, 2024
CY2023Q1	gthp	Vesting Period Description VestingPeriodDescription	One fourth of the stock options vested immediately, while the remaining options will vest over a period of 33 months, beginning on May 10, 2023
CY2024Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	82053	usd
	gthp	Payment To Consultant PaymentToConsultant	2000	usd
CY2024Q3	us-gaap	Notes Payable NotesPayable	50000	usd
CY2024Q3	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	5000	usd
CY2024Q3	us-gaap	Repayments Of Debt RepaymentsOfDebt	10000	usd
CY2024Q3	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2025-01-01
CY2024Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.25
CY2024Q2	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	10000	usd
CY2024Q2	us-gaap	Repayments Of Debt RepaymentsOfDebt	20000	usd
CY2024Q2	gthp	Common Stock Purchase Warrants CommonStockPurchaseWarrants	100000	shares
CY2024Q3	us-gaap	Line Of Credit Facility Average Outstanding Amount LineOfCreditFacilityAverageOutstandingAmount	129556	usd
CY2024Q3	us-gaap	Repayments Of Debt RepaymentsOfDebt	12025	usd
CY2024Q3	gthp	Accrued Interest Rate AccruedInterestRate	0.088	pure
CY2024Q3	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2025-05-04
CY2024Q3	gthp	Outstanding Principal Balance Note Payable OutstandingPrincipalBalanceNotePayable	59422	usd
CY2024Q3	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	228000	usd
CY2023Q4	us-gaap	Short Term Bank Loans And Notes Payable ShortTermBankLoansAndNotesPayable	59000	usd
CY2022Q3	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.15
CY2022Q3	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	0.20
CY2024Q3	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	75000	usd
CY2023Q4	us-gaap	Short Term Non Bank Loans And Notes Payable ShortTermNonBankLoansAndNotesPayable	0	usd
CY2024Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	7000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	0	usd
CY2024Q3	gthp	Short Term Notes Payable Due To Related Parties ShortTermNotesPayableDueToRelatedParties	68000	usd
CY2023Q4	gthp	Short Term Notes Payable Due To Related Parties ShortTermNotesPayableDueToRelatedParties	0	usd
CY2024Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	20000	usd
	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	100000	shares

Files In Submission

Name	View Source	Status
0001477932-24-007162-index-headers.html	Edgar Link	pending
0001477932-24-007162-index.html	Edgar Link	pending
0001477932-24-007162.txt	Edgar Link	pending
0001477932-24-007162-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
gthp-20240930.xsd	Edgar Link	pending
gthp_10q.htm	Edgar Link	pending
gthp_ex101.htm	Edgar Link	pending
gthp_ex102.htm	Edgar Link	pending
gthp_ex103.htm	Edgar Link	pending
gthp_ex104.htm	Edgar Link	pending
gthp_ex31.htm	Edgar Link	pending
gthp_ex32.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
gthp_10q_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
gthp-20240930_lab.xml	Edgar Link	unprocessable
gthp-20240930_cal.xml	Edgar Link	unprocessable
gthp-20240930_def.xml	Edgar Link	unprocessable
gthp-20240930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GTHP
GUIDED THERAPEUTICS INC Stock $gthp

2024 Q4 Form 10-Q Financial Statement

#000147793224007162 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GTHP GUIDED THERAPEUTICS INC Stock $gthp

2024 Q4 Form 10-Q Financial Statement

#000147793224007162 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GTHP
GUIDED THERAPEUTICS INC Stock $gthp